期刊文献+

Construction, expression and characterization of human interferon α2b-(G4S)n-thymosin α1 fusion proteins in Pichia pastoris 被引量:5

Construction, expression and characterization of human interferon α2b-(G4S)n-thymosin α1 fusion proteins in Pichia pastoris
在线阅读 下载PDF
导出
摘要 AIM:Interferon α2b (IFNα2b) and thymosin α1 (Tα1) exhibit synergic effects in the treatment of hepatitis B and hepatitis C when used together. For developing a fusion protein drug, fusion proteins of IFNα2b and Ta1 linked by different lengths of (G4S)n(n = 1-3) were constructed and expressed in Pichia pastoris. METHODS: Using PCR and molecular clone techniques, the fusion genes of IFNα2b-(G4S)n-Tα1 (n = 1-3) were constructed and subcloned into the eukaryotic expression vector pPIC9. After transformation of these plasmids into P. pastoris, the expressed fusion proteins IFNα2b-(G4S) n-Tα1 (n = 1-3) were obtained. These proteins were purified through diethylaminoethyl (DEAE) affinity chromatography and Superdex?75 gel filtration and analyzed by SDS-PAGE and Western blot. Antiviral and E-rosette assays were used to investigate the bioactivities of these fusion proteins. RESULTS: DNA sequencing confirmed that the fusion genes of IFNa2b-(G4S)n-Tα1 (n= 1-3) were correctly cloned to the pPIC9 vector. The recombinant IFNα2b-(G4S)n-Tα1 (n = 1-3) fusion proteins expressed in P. pastoris were purified with DEAE and Superdex?75 gel filtration chromatography. The fusion proteins could be observed on sodium dodecylsulfate-polyacrylamide gel electrophoresis with molecular weight (MW) of 23.2, 22.9, and 22.6 ku, respectively, and reacted to the IFNa2b monoclonal antibody and Tal polyclonal antibody. The purified fusion proteins exhibit antiviral activity and can enhance the percentage of E-rosette-forming-cell in E-rosette assay. CONCLUSION: The recombinant IFNa2b-(G4S)n-Tα1 (n = 1-3) fusion proteins were successfully expressed in P. pastoris. Purified fusion proteins exhibit both antiviral activity of IFNa2b and immunomodulatory activity of Tal in vitro. These results will be the basis for further evaluation of the fusion proteins' function in vivo. AIM: Interferon α2b (IFNα2b) and thymosin α1 (Tα1) exhibit synergic effects in the treatment of hepatitis B and hepatitis C when used together. For developing a fusion protein drug, fusion proteins of IFNα2b and Tα1 linked by different lengths of (G4S)n (n = 1-3) were constructed and expressed in Pichia pastoris.METHODS: Using PCR and molecular clone techniques, the fusion genes of IFNα2b-(G4S)n-Tα1 (n = 1-3) were constructed and subcloned into the eukaryotic expression vector pPIC9. After transformation of these plasmids into P. pastoris, the expressed fusion proteins IFNα2b-(G4S)n-Tα1 (n = 1-3) were obtained. These proteins were purified through diethylaminoethyl (DEAE) affinity chromatography and SuperdexTM 75 gel filtration and analyzed by SDSPAGE and Western blot. Antiviral and E-rosette assays were used to investigate the bioactivities of these fusion proteins.RESULTS: DNA sequencing confirmed that the fusion genes of IFNα2b-(G4 S)n-Tα1 (n = 1-3) were correctly cloned to the pPIC9 vector. The recombinant IFNα2b(G4 S)n-Tα1 (n = 1-3) fusion proteins expressed in P. pastoris were purified with DEAE and SuperdexTM 75 gel filtration chromatography. The fusion proteins could be observed on sodium dodecylsulfate-polyacrylamide gel electrophoresis with molecular weight (MW) of 23.2, 22.9, and 22.6 ku, respectively, and reacted to the IFNα2b monoclonal antibody and Tα1 polyclonal antibody. The purified fusion proteins exhibit antiviral activity and can enhance the percentage of E-rosette-forming-cell in E-rosette assay.CONCLUSION: The recombinant IFNα2b-(G4S)n-Tα1 (n = 1-3) fusion proteins were successfully expressed in P. pastoris. Purified fusion proteins exhibit both antiviral activity of IFNα2b and immunomodulatory activity of Tα1 in vitro. These results will be the basis for further evaluation of the fusion proteins' function in vivo.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第17期2597-2602,共6页 世界胃肠病学杂志(英文版)
关键词 Fusion protein Interferon α2b Thymosin al Antiviral assay E-rosette assay 干扰素α2b 胸腺素α1 溶解蛋白 乙型肝炎 丙型肝炎
  • 相关文献

参考文献28

  • 1DI B, Martin P, Lisker-Melman M, Kassianides C, KorenmanJ, Bergasa NV, Baker B, Hoofnagle JH. Therapy of chronic delta hepatitis with interferon alfa-2b. J Hepatol 1990; 11(Suppl 1): 151-154.
  • 2Tamayo L, Ortiz DM, Orozco-Covarrubias L, Duran-McKinster C, Mora MA, Avila E, Teixeira F, Ruiz-Maldonado R. Therapeutic efficacy of interferon alfa-2b in infants with life-threatening giant hemangiomas. Arch Dermatol 1997;133:1567-1571.
  • 3Romerio F, Zella D. MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. FASEB J 2002;16:1680-1682.
  • 4Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm 2001; 58:879-885.
  • 5Billich A. Thymosin alphal. SciClone Pharmaceuticals. Curr Opin Investig Drugs 2002; 3:698-707.
  • 6Rothstein KD, Munoz SJ. Interferon and other therapies for hepatitis B and hepatitis C infections. Clin Lab Med 1996; 16:465-491.
  • 7Molloy PJ, Azzouz M, Van T. Treatment of chronic hepatitis B and hepatitis C with interferon alfa-2b. Am Faro Physician1996; 54:1598-1605.
  • 8Arase Y, Tsubota A, Suzuki Y, Suzuki F, Kobayashi M,Someya T, Akuta N, Hosaka T, Saitoh S, Ikeda K, Kobayashi M, Kumada H. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Intern Med 2003; 42:941-946.
  • 9Saruc M, Yuceyar H, Kucukmetin N, Demir MA, Kandiloglu AR. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenteroloygy 2002; 49: 798-802.
  • 10Saruc M, Ozden N, Turkel N, Ayhan S, Hock LM, Tuzcuoglu I, Yuceyar H. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci 2003; 92: 1386-1395.

同被引文献27

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部